{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:52:23Z","timestamp":1776779543605,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00292-018-0516-9","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T09:04:36Z","timestamp":1553072676000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Urachal cancer\u2014current concepts of a\u00a0rare cancer","Das Urachuskarzinom \u2013 aktuelle Konzepte einer seltenen Tumorerkrankung"],"prefix":"10.1007","volume":"40","author":[{"given":"H.","family":"Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","volume":"5","author":"DH Aggen","year":"2017","unstructured":"Aggen DH, Drake CG (2017) Biomarkers for immunotherapy in bladder cancer: a\u00a0moving target. J\u00a0Immunother Cancer 5:94","journal-title":"J Immunother Cancer"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/PAS.0000000000000250","volume":"38","author":"MB Amin","year":"2014","unstructured":"Amin MB, Smith SC, Eble JN et\u00a0al (2014) Glandular neoplasms of the urachus: a\u00a0report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol 38:1033\u20131045","journal-title":"Am J Surg Pathol"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cncr.22060","volume":"107","author":"RA Ashley","year":"2006","unstructured":"Ashley RA, Inman BA, Sebo TJ et al (2006) Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 107:712\u2013720","journal-title":"Cancer"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a\u00a0phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"516_CR5","first-page":"170","volume":"64","author":"RC Begg","year":"1930","unstructured":"Begg RC (1930) The urachus: its anatomy, histology and development. J\u00a0Anat 64:170\u2013183","journal-title":"J Anat"},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073\u20132087 (e2073)","journal-title":"Gastroenterology"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.juro.2012.06.020","volume":"188","author":"HM Bruins","year":"2012","unstructured":"Bruins HM, Visser O, Ploeg M et\u00a0al (2012) The clinical epidemiology of urachal carcinoma: results of a\u00a0large, population based study. J\u00a0Urol 188:1102\u20131107","journal-title":"J Urol"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-016-2209-1","volume":"16","author":"S Cha","year":"2016","unstructured":"Cha S, Lee J, Shin JY et\u00a0al (2016) Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer 16:170","journal-title":"BMC Cancer"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.eururo.2016.04.037","volume":"70","author":"A Collazo-Lorduy","year":"2016","unstructured":"Collazo-Lorduy A, Castillo-Martin M, Wang L et al (2016) Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition. Eur Urol 70:771\u2013775","journal-title":"Eur Urol"},{"key":"516_CR10","volume-title":"Embryology, anatomy, and diseases of the umbilicus: together with diseases of the urachus","author":"TS Cullen","year":"1916","unstructured":"Cullen TS (1916) Embryology, anatomy, and diseases of the umbilicus: together with diseases of the urachus. Saunders, Philadelphia"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.humpath.2015.07.021","volume":"46","author":"J Dhillon","year":"2015","unstructured":"Dhillon J, Liang Y, Kamat AM et\u00a0al (2015) Urachal carcinoma: a\u00a0pathologic and clinical study of 46 cases. Hum Pathol 46:1808\u20131814","journal-title":"Hum Pathol"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/PAS.0b013e31819aa4ae","volume":"33","author":"A Gopalan","year":"2009","unstructured":"Gopalan A, Sharp DS, Fine SW et\u00a0al (2009) Urachal carcinoma: a\u00a0clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 33:659\u2013668","journal-title":"Am J Surg Pathol"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-M","volume":"67","author":"DJ Grignon","year":"1991","unstructured":"Grignon DJ, Ro JY, Ayala AG et\u00a0al (1991) Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 67:2165\u20132172","journal-title":"Cancer"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.pathol.2016.11.017","volume":"49","author":"JF Hang","year":"2017","unstructured":"Hang JF, Pan CC (2017) Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma. Pathology 49:316\u2013317","journal-title":"Pathology"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.juro.2007.03.022","volume":"178","author":"HW Herr","year":"2007","unstructured":"Herr HW, Bochner BH, Sharp D et\u00a0al (2007) Urachal carcinoma: contemporary surgical outcomes. J\u00a0Urol 178:74\u201378","journal-title":"J Urol"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1200\/JCO.2017.35.15_suppl.4511","volume":"35","author":"G Iyer","year":"2017","unstructured":"Iyer G, Audenet F, Middha S et\u00a0al (2017) Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. J\u00a0Clin Oncol 35:4511\u20134511","journal-title":"J Clin Oncol"},{"key":"516_CR17","first-page":"418","volume":"6","author":"HA Jacquin","year":"1863","unstructured":"Jacquin HA (1863) Cancer colloide de l\u2019ombilic et de la paroi abdominale anterieure ayant envahi la vessie. Union Med 6:418","journal-title":"Union Med."},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000368071","volume":"60","author":"HA Jung","year":"2014","unstructured":"Jung HA, Sun JM, Park SH et\u00a0al (2014) Treatment outcome and relevance of palliative chemotherapy in urachal cancer. Chemotherapy 60:73\u201380","journal-title":"Chemotherapy"},{"key":"516_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00027","volume":"1","author":"J Kardos","year":"2017","unstructured":"Kardos J, Wobker SE, Woods ME et\u00a0al (2017) Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a\u00a0hypermutable phenotype. JCO Precis Oncol 1:1\u201312","journal-title":"JCO Precis. Oncol."},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.4111\/kju.2014.55.9.574","volume":"55","author":"IK Kim","year":"2014","unstructured":"Kim IK, Lee JY, Kwon JK et al (2014) Prognostic factors for urachal cancer: a\u00a0bayesian model-averaging approach. Korean J Urol 55:574\u2013580","journal-title":"Korean J Urol"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.clgc.2016.03.013","volume":"14","author":"KP Loh","year":"2016","unstructured":"Loh KP, Mondo E, Hansen EA et\u00a0al (2016) Targeted therapy based on tumor genomic analyses in metastatic urachal carcinoma. Clin Genitourin Cancer 14:e449\u2013452","journal-title":"Clin Genitourin Cancer"},{"key":"516_CR22","first-page":"113","volume-title":"World Health Organization classification of tumours of the urinary system and male genital organs","author":"A Lopez-Beltran","year":"2016","unstructured":"Lopez-Beltran A, Paner G, Tsuzuki T (2016) Urachal carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds) World Health Organization classification of tumours of the urinary system and male genital organs. IARC, Lyon, pp 113\u2013114"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"39293","DOI":"10.18632\/oncotarget.9828","volume":"7","author":"O Modos","year":"2016","unstructured":"Modos O, Reis H, Niedworok C et\u00a0al (2016) Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: occurence and prognostic significance. Oncotarget 7:39293\u201339301","journal-title":"Oncotarget"},{"key":"516_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/1097-0142(1955)8:4<741::AID-CNCR2820080417>3.0.CO;2-C","volume":"8","author":"FK Mostofi","year":"1955","unstructured":"Mostofi FK, Thomson RV, Dean AL Jr. (1955) Mucous adenocarcinoma of the urinary bladder. Cancer 8:741\u2013758","journal-title":"Cancer"},{"key":"516_CR25","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.juro.2015.11.067","volume":"195","author":"C Niedworok","year":"2016","unstructured":"Niedworok C, Panitz M, Szarvas T et\u00a0al (2016) Urachal carcinoma of the bladder: impact of clinical and Immunohistochemical parameters on prognosis. J\u00a0Urol 195:1690\u20131696","journal-title":"J Urol"},{"key":"516_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.eururo.2016.07.004","volume":"70","author":"P Nyirady","year":"2016","unstructured":"Nyirady P, Niedworok C, Reis H et al (2016) Clinical sequencing-guided therapy of urachal carcinoma: new perspective for a\u00a0rare cancer. Eur Urol 70:776\u2013777","journal-title":"Eur Urol"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/PAS.0b013e31823fe49c","volume":"36","author":"GP Paner","year":"2012","unstructured":"Paner GP, Barkan GA, Mehta V et\u00a0al (2012) Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis. Am J Surg Pathol 36:432\u2013442","journal-title":"Am J Surg Pathol"},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/PAP.0000000000000110","volume":"23","author":"GP Paner","year":"2016","unstructured":"Paner GP, Lopez-Beltran A, Sirohi D et al (2016) Updates in the pathologic diagnosis and classification of epithelial neoplasms of urachal origin. Adv Anat Pathol 23:71\u201383","journal-title":"Adv Anat Pathol"},{"key":"516_CR29","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/S0022-5347(06)00263-1","volume":"175","author":"JH Pinthus","year":"2006","unstructured":"Pinthus JH, Haddad R, Trachtenberg J et\u00a0al (2006) Population based survival data on urachal tumors. J\u00a0Urol 175:2042\u20132047","journal-title":"J Urol"},{"key":"516_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31547","author":"H Reis","year":"2018","unstructured":"Reis H, Van Der Vos KE, Niedworok C et\u00a0al (2018) Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.31547","journal-title":"Int J Cancer"},{"key":"516_CR31","doi-asserted-by":"publisher","first-page":"7308168","DOI":"10.1155\/2018\/7308168","volume":"2018","author":"H Reis","year":"2018","unstructured":"Reis H, Krafft U, Niedworok C et\u00a0al (2018) Biomarkers in urachal cancer and adenocarcinomas in the bladder: a\u00a0comprehensive review supplemented by own data. Dis Markers 2018:7308168","journal-title":"Dis Markers"},{"key":"516_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0022-5347(17)53595-8","volume":"127","author":"GE Schubert","year":"1982","unstructured":"Schubert GE, Pavkovic MB, Bethke-Bed\u00fcrftig BA (1982) Tubular urachal remnants in adult bladders. J\u00a0Urol 127:40\u201342","journal-title":"J Urol"},{"key":"516_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-5347(17)50167-6","volume":"131","author":"CA Sheldon","year":"1984","unstructured":"Sheldon CA, Clayman RV, Gonzalez R et\u00a0al (1984) Malignant urachal lesions. J\u00a0Urol 131:1\u20138","journal-title":"J Urol"},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.seminoncol.2012.08.011","volume":"39","author":"A Siefker-Radtke","year":"2012","unstructured":"Siefker-Radtke A (2012) Urachal adenocarcinoma: a\u00a0clinician\u2019s guide for treatment. Semin Oncol 39:619\u2013624","journal-title":"Semin Oncol"},{"key":"516_CR35","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1586\/14737140.6.12.1715","volume":"6","author":"A Siefker-Radtke","year":"2006","unstructured":"Siefker-Radtke A (2006) Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6:1715\u20131721","journal-title":"Expert Rev Anticancer Ther"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/01.ju.0000054646.49381.01","volume":"169","author":"AO Siefker-Radtke","year":"2003","unstructured":"Siefker-Radtke AO, Gee J, Shen Y et al (2003) Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J\u00a0Urol 169:1295\u20131298","journal-title":"J Urol"},{"key":"516_CR37","doi-asserted-by":"crossref","first-page":"29211","DOI":"10.18632\/oncotarget.8640","volume":"7","author":"H Singh","year":"2016","unstructured":"Singh H, Liu Y, Xiao X et\u00a0al (2016) Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget 7:29211\u201329215","journal-title":"Oncotarget"},{"key":"516_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.humpath.2013.09.008","volume":"45","author":"SJ Sirintrapun","year":"2014","unstructured":"Sirintrapun SJ, Ward M, Woo J et al (2014) High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol 45:327\u2013330","journal-title":"Hum Pathol"},{"key":"516_CR39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a\u00a0monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N\u00a0Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"516_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","volume":"34","author":"T Szarvas","year":"2016","unstructured":"Szarvas T, Modos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Urol Oncol 34:388\u2013398","journal-title":"Urol Oncol"},{"key":"516_CR41","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330\u2013337","journal-title":"Nature"},{"key":"516_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"The Cancer Genome Atlas Network","year":"2014","unstructured":"The Cancer Genome Atlas Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315\u2013322","journal-title":"Nature"},{"key":"516_CR43","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3109\/0284186X.2014.895036","volume":"53","author":"C Therkildsen","year":"2014","unstructured":"Therkildsen C, Bergmann TK, Henrichsen-Schnack T et al (2014) The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 53:852\u2013864","journal-title":"Acta Oncol"},{"key":"516_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/pin.12594","volume":"67","author":"S Thiem","year":"2017","unstructured":"Thiem S, Herold T, Krafft U et\u00a0al (2017) Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. Pathol Int 67:597\u2013601","journal-title":"Pathol Int"},{"key":"516_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1055\/s-2003-44725","volume":"13","author":"V Upadhyay","year":"2003","unstructured":"Upadhyay V, Kukkady A (2003) Urachal remnants: an enigma. Eur J Pediatr Surg 13:372\u2013376","journal-title":"Eur J Pediatr Surg"},{"key":"516_CR46","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"Vinagre J, Almeida A, Populo H et\u00a0al (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185","journal-title":"Nat Commun"},{"key":"516_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/1097-0142(195401)7:1<119::AID-CNCR2820070113>3.0.CO;2-8","volume":"7","author":"JD Wheeler","year":"1954","unstructured":"Wheeler JD, Hill WT (1954) Adenocarcinoma involving the urinary bladder. Cancer 7:119\u2013135","journal-title":"Cancer"},{"key":"516_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/cncr.22059","volume":"107","author":"JL Wright","year":"2006","unstructured":"Wright JL, Porter MP, Li CI et\u00a0al (2006) Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 107:721\u2013728","journal-title":"Cancer"},{"key":"516_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2013.10.038","volume":"65","author":"S Wu","year":"2014","unstructured":"Wu S, Huang P, Li C et\u00a0al (2014) Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a\u00a0genomic and molecular study. Eur Urol 65:274\u2013277","journal-title":"Eur Urol"},{"key":"516_CR50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000362400","volume":"59","author":"Y Yanagihara","year":"2013","unstructured":"Yanagihara Y, Tanji N, Miura N et\u00a0al (2013) Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy 59:402\u2013406","journal-title":"Chemotherapy"}],"container-title":["Der Pathologe"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-018-0516-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T23:12:49Z","timestamp":1721085169000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-018-0516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":50,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s00292-018-0516-9","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"20 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"H.\u00a0Reis and T.\u00a0Szarvas declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}